Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The combination of the active pharmaceutical ingredients furosemide [4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid] and pentoxifylline [3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione] produces a 1:1 cocrystal, C(12)H(11)ClN(2)O(5)S·C(13)H(18)N(4)O(3), (I), a 1:1 cocrystal hydrate, C(12)H(11)ClN(2)O(5)S·C(13)H(18)N(4)O(3)·H(2)O, (II), and a 1:1 cocrystal acetone solvate, C(12)H(11)ClN(2)O(5)S·C(13)H(18)N(4)O(3)·C(2)H(6)O, (III). These structures exhibit the presence of a rarely encountered synthon with the graph set R(2)(2)(7). All potential hydrogen-bond donors of furosemide participate in hydrogen-bond formation in (I)-(III). However, only two hydrogen-bond acceptors of furosemide are active in (I) and (II), and only one is active in (III). Four hydrogen-bond acceptors of pentoxifylline are active in (II), three in (I) and two in (III). These observations are in good agreement with the calculated packing indexes of 69.5, 69.6 and 68.8% for (II), (I) and (III), respectively.

Citation

Dmitrijs Stepanovs, Anatoly Mishnev. Multicomponent pharmaceutical cocrystals: furosemide and pentoxifylline. Acta crystallographica. Section C, Crystal structure communications. 2012 Dec;68(Pt 12):o488-91

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 23221253

View Full Text